Russia Ministry of Health Approves Avifavir (Favipiravir) for COVID-19 Patients

Russia’s Ministry of Health issued a temporary registration certificate announcing that Avifavir became the world’s first Favipiravir-based drug to be approved for the treatment of COVID-19. TrialSite News has reported that this class of drug has shown some promise in clinical trials in Japan; it was also being studied by Massachusetts General Hospital and Brigham and Women’s Hospital in the form of Avigan. To get more news about 259793-96-9, wisepowder official website is the best place for you.
Now the Russia Federation has actually approved the drug based on notable efficacy in patients diagnosed with COVID-19. The drug was currently under investigation in a number of cities—from Moscow and Saint-Petersburg to Kazan and Ufa as well as the Republic of Dagestan.
TrialSite News first introduced Avigan (Favipiravir) and received many direct emails of interest all over the world including the United States. Known as Avigan, it is an antiviral drug under development by Toyama Chemical of Japan and exhibits effective activity against many RNA viruses. The drug has also been assessed in China for experimental treatment of SARS-CoV-2 and was found to be effective in treating the infection in two clinical trials in Wuhan and Shenzhen.
In fact, by February 17, 2020, the head of the China National Center for Biotechnology Department, Zhang Xinmin, reported that the drug showed favorable anti-influenza qualities based on clinical trials in Shenzhen, Guangdong province reported Precision Vaccinations.
Avigan has evidenced activity against influenza viruses, West Nile virus, yellow fever virus, foot and mouth disease and others.
The global manufacturer and intellectual property owner is Japan’s Fujifilm Holdings Corp and its subsidiary Fujifilm Toyama Chemical Co., Ltd. The Japanese company has a mandate from the Japanese government to produce up to 2 million doses for COVID-19 patients by March 2021 as part of the war on the COVID-19 pandemic.
In Russia, the drug trials were supported by a couple companies, including the ChemRar Group and RDIF who led local production of the drug. Apparently, ChemRar Group combines R&D services, drug development investment, manufacturing and commercialization to help improve care and prevent life-threatening diseases in Russia and abroad. Investment fund RDIF owns 50% of drug maker ChemRar and helped fund the studies, totaling about 300 million rubles ($4.3 million).